RemeGen Co., Ltd., a leader in biopharmaceutical innovation based in China, has unveiled promising results from its Phase I/II clinical study of RC88, a first-in-class antibody-drug conjugate (ADC), at the American Society of Clinical Oncology Annual Meeting (ASCO 2024) in Chicago. The study focuses on the efficacy and safety of RC88 in treating advanced solid […]
RemeGen, a commercial-stage Chinese biotechnology firm, and Innovent Biologics have announced their collaboration in a clinical research and supply agreement. This partnership focuses on conducting clinical trials that explore combination therapies involving novel antibody-drug conjugates (ADCs), specifically, RC88 and RC108, and the PD-1 inhibitor sintilimab injection, TYVYT. As per the agreement, Innovent Biologics will supply […]
